Loading...
BIOR.Q logo

Biora Therapeutics, Inc.OTCPK:BIOR.Q Stock Report

Market Cap US$597.1k
Share Price
US$0.0003
My Fair Value
n/a
1Y-97.8%
7D-5.3%
Portfolio Value
​
View

Biora Therapeutics, Inc.

OTCPK:BIOR.Q Stock Report

Market Cap: US$597.1k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Biora Therapeutics (BIOR.Q) Stock Overview

A clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. More details

BIOR.Q fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Rewards

Earnings have grown 21.3% per year over the past 5 years

Risk Analysis

Negative shareholders equity

Makes less than USD$1m in revenue ($892K)

Does not have a meaningful market cap ($597K)

Highly volatile share price over the past 3 months compared to the US market

+ 1 more risk

BIOR.Q Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Biora Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Biora Therapeutics
Historical stock prices
Current Share PriceUS$0.14
52 Week HighUS$7.90
52 Week LowUS$0.08
Beta1.25
1 Month Change3.85%
3 Month Change6.34%
1 Year Change-97.77%
3 Year Change-99.94%
5 Year Changen/a
Change since IPO-100.00%

Recent News & Updates

Recent updates

Seeking Alpha • Sep 13

Biora Therapeutics granted patent for oral delivery of GLP-1 receptor agonists

Biora Therapeutics (NASDAQ:BIOR) said on Tuesday the United States Patent and Trademark Office had issued a patent related to the company’s technologies for oral, systemic delivery of biologics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the small intestine. The patent is for methods for using an ingestible device to treat a disease or condition in a patient using jet delivery of a glucagon receptor agonist or a glucagon-like peptide-1 (GLP-1) receptor agonist formulation to the small intestine. GLP-1 receptor agonists are a class of drug approved for type 2 diabetes and weight loss.
Seeking Alpha • Aug 17

Biora Therapeutics: Checking In On The Transformation

Today, we take our first look at the rebranded/refocused Biora Therapeutics in 2022. When we last looked at this company, it was still transitioning from being a genetic testing company to being a developmental drug company. How is the transformation working out to date?  An investment analysis follows in the paragraphs below. Everyone thinks of changing the world, but no one thinks of changing himself." - Leo Tolstoy Today, we put Biora Therapeutics (BIOR) in the spotlight for the first time this year. When we last looked at this entity in the fourth quarter of last year, it was still transitioning from being an entity called Progenity (PROG). The company was in the middle of transforming from its focus as a genetic testing company to being a company focused on developing its drug candidates. Second quarter results just hit the wires this week. Therefore, it seems an opportune time to peak back in on this small cap concern and check in on how its transformation is proceeding. An analysis follows below. Seeking Alpha Company Overview: August Company Presentation The refocused Biora Therapeutics is still based in San Diego. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the GI tract to enhance the treatment of inflammatory bowel diseases. Leadership believe this approach has plenty of potential targets, including holding great promise to more effectively treat Ulcerative Colitis, a large indication. It also is targeting IBD. According to management on its last earnings conference call. Annual global sales for UC drugs are estimated to be approximately $7 billion and the inflammatory bowel disease or IBD space overall is about $19 billion globally. " August Company Presentation August Company Presentation Here is the current development plan for the most advanced candidate in this developmental area, PGN - 600, which is combination of Biora's device and their proprietary formulation of tofacitinib. August Company Presentation The company is also focused on an oral delivery approach via ingestible capsules as an alternative to intramuscular injectable vaccines. This method could eventually see use for proteins as well as monoclonal antibodies. August Company Presentation The replacement of needle injection via an easy to take oral capsule could yield more effective results in a variety of disease areas. The company has a research collaboration with Ionis Pharmaceuticals (IONS) in these initial efforts. Preclinical activities should run into the third quarter of 2023, and are scheduled to start early stage clinical activities by the end of that year. The company estimates the area of the diabetes market it is targeting to be well over $20 billion by 2025. August Company Presentation Management believes the management of diabetes could be vastly improved to name one large target area. August Company Presentation With two core developmental focus areas, the company has numerous candidates in the pipeline. The company's portfolio has numerous patents around the company's intellectual property. That said, its candidates all in the very early stages of the long developmental lifecycle as can be seen above. August Company Presentation
Seeking Alpha • Aug 10

Biora rallies 30%, highest since November on data for drug delivery device

Biora Therapeutics (NASDAQ:BIOR), a biotech focused on oral biotherapeutics, surged ~30% on Wednesday to record the highest intraday gain since November after the company announced promising topline data from a study for its targeted therapeutics platform. The recently completed PM-602 was designed to evaluate the Drug Delivery System Capsule (DDS) in patients with ulcerative colitis in a fasted state. According to the data, the device was well tolerated and performed as expected in all UC patients after a single oral ingestion. Accurately identifying the entry into the colon, the device released a saline solution payload that included radioisotopes, leading to distribution across the entire colon in all seven patients. Biora (BIOR) plans to release further information on the study after completing the analysis and intends to submit data for publication. “These human studies are key steps in advancing toward our PGN-600 clinical program, and they also demonstrate the potential of the platform for localized delivery of other drugs,” Chief Executive Adi Mohanty noted. Biora (BIOR) was previously identified as Progenity.

Shareholder Returns

BIOR.QUS BiotechsUS Market
7D-5.3%-3.0%-0.3%
1Y-97.8%32.9%26.7%

Return vs Industry: BIOR.Q underperformed the US Biotechs industry which returned -12.9% over the past year.

Return vs Market: BIOR.Q underperformed the US Market which returned 9.1% over the past year.

Price Volatility

Is BIOR.Q's price volatile compared to industry and market?
BIOR.Q volatility
BIOR.Q Average Weekly Movement25.6%
Biotechs Industry Average Movement10.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.2%

Stable Share Price: BIOR.Q's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: BIOR.Q's weekly volatility (26%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201058Adi Mohantywww.bioratherapeutics.com

Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline.

Biora Therapeutics, Inc. Fundamentals Summary

How do Biora Therapeutics's earnings and revenue compare to its market cap?
BIOR.Q fundamental statistics
Market capUS$597.11k
Earnings (TTM)-US$35.57m
Revenue (TTM)US$892.00k
0.7x
P/S Ratio
0.0x
P/E Ratio

Is BIOR.Q overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BIOR.Q income statement (TTM)
RevenueUS$892.00k
Cost of RevenueUS$0
Gross ProfitUS$892.00k
Other ExpensesUS$36.47m
Earnings-US$35.57m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-8.04
Gross Margin100.00%
Net Profit Margin-3,988.12%
Debt/Equity Ratio-36.9%

How did BIOR.Q perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/27 16:39
End of Day Share Price 2025/05/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Biora Therapeutics, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Catherine Ramsey SchulteBaird
Steven MahPiper Sandler Companies
Andrew CooperRaymond James & Associates